Ascendiant Capital Markets Has Lowered Expectations for Atossa Genetics (NASDAQ:ATOS) Stock Price

Atossa Genetics (NASDAQ:ATOS) had its price target lowered by stock analysts at Ascendiant Capital Markets from $120.00 to $24.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price suggests a potential upside of 385.83% from the stock’s previous close.

Other analysts have also issued research reports about the stock. HC Wainwright lifted their target price on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.33.

Atossa Genetics Stock Performance

NASDAQ:ATOS opened at $4.94 on Friday. The firm’s 50-day moving average is $4.84 and its 200-day moving average is $9.40. Atossa Genetics has a 52-week low of $3.76 and a 52-week high of $19.35. The company has a market cap of $42.53 million, a price-to-earnings ratio of -1.37 and a beta of 1.34.

Institutional Investors Weigh In On Atossa Genetics

Several large investors have recently bought and sold shares of ATOS. Renaissance Technologies LLC increased its position in shares of Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares in the last quarter. State Street Corp increased its position in shares of Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares in the last quarter. Qube Research & Technologies Ltd increased its position in shares of Atossa Genetics by 357.4% during the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Atossa Genetics by 39.9% during the third quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Atossa Genetics by 55.8% during the third quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock worth $135,000 after acquiring an additional 55,568 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.